Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Company Overview - The company is experiencing a significant year with excitement surrounding the progress made in the previous year [1] - The company is preparing to launch its first two in vivo liver-directed programs, targeting Wilson disease and alpha-1 antitrypsin deficiency [1] - Regulatory submissions (IND/CTAs) for Wilson disease are expected in the first half of the year, while submissions for alpha-1 antitrypsin deficiency are anticipated in the middle of the year [1]